Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Surgery Clinical Trial

Official title:

Pilot Study of Perampanel on Peritumoral Hyperexcitability and Seizure Control in Newly Diagnosed High Grade Glioma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04497142
• Other study ID #: 20-059
• Secondary ID: 2P50CA165962-06A
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 5, 2020
• Est. completion date: May 16, 2023

Study information

• Verified date: August 2023
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to learn more about seizures in people with primary brain tumors. It will evaluate whether an antiseizure medication decreases hyperexcitability activity around tumors and prevents seizures. The procedure and study drug involved in this study are: - Electrocorticography - Perampanel (Fycompa)

Description:

This research study is a Pilot Study, which is the first time investigators are examining brain activity after taking perampanel. The U.S. Food and Drug Administration (FDA) has approved perampanel as a treatment option for seizures. It has not been approved for the treatment of brain tumors. Recording of brain activity (electrocorticography) during surgery is an established clinical procedure, which will be performed for investigational purposes. This research study is studying brain recordings and perampanel treatment in participants with brain tumors for the following reasons: - People with brain tumors commonly have seizures. - Perampanel was developed as an anti-seizure medication, which works by blocking a signaling pathway between brain cells, mediated by AMPA receptors. - Previous research has shown abnormal brain activity around tumors resulting from increased AMPA receptor activation. - Perampanel is expected to decrease abnormal brain activity and prevent seizures by blocking AMPA receptor signaling. This study involves two groups of participants, one group who receives the antiseizure medication perampanel, and the other group who receives the usual antiseizure medication (typically levetiracetam) at the time of surgery. Participants have the option to choose which group to participate if they have a preference. The research study procedures include screening for eligibility, recording brain activity during surgery, and study treatment including evaluations and follow up visits. Participants will receive the study drug for as long as they do not have serious side effects and their disease does not get worse, up to a maximum of 12 months. It is expected that about 20 people will take part in this research study. The National Institute of Health (NIH) is supporting this study by providing funding for the research. Eisai Inc, a pharmaceutical company, is supporting this research study by providing the study medication.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: May 16, 2023
• Est. primary completion date: May 16, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must have radiologic evidence of anaplastic astrocytoma or glioblastoma multiforme within 14 days of enrollment.
• Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as =10 mm (=1 cm) with CT or MRI. See Section 11 (Measurement of Effect) for the evaluation of measurable disease.
• Age =18 years.
• ECOG performance status =2 (Karnofsky =60%, see Appendix A).
• Participants must have adequate organ and marrow function as defined below:
• absolute neutrophil count =1,500/mcL
• platelets =100,000/mcL
• total bilirubin = institutional upper limit of normal (ULN)
• AST(SGOT)/ALT(SGPT) =3 × institutional ULN
• glomerular filtration rate (GFR) = 30 mL/min/1.73 m2 (see Appendix B)
• Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
• For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
• Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
• Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
• Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
• The effects of perampanel on the developing human fetus are unknown. For this reason and because some anti-seizure medications are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Participants with brain metastases due to confounding effects on the study objectives.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to perampanel.
• Participants receiving any medications or substances that are moderate or strong inducers of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
• Participants with uncontrolled intercurrent illness.
• Participants with psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women are excluded from this study because perampanel is an anti-seizure agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with perampanel, breastfeeding should be discontinued if the mother is treated with perampanel.
• Participants with a history of suicide attempt or current active suicidal ideation with intent as defined by Columbia Suicide Severity Rating Scale (C-SSRS) type 4-5, due to the potential for suicidal ideation with the use of all anti-seizure medications.
• Participants who are unable to swallow pills.
• Participants with tumor associated seizures greater than one month before planned surgery.
• Participants currently receiving treatment with more than one anti-seizure medication.

Related Conditions & MeSH terms

• Glioma
• Glioma, Malignant
• Seizures
• Surgery

Intervention

Drug:
• Perampanel
Tablet taken orally 1x daily.
• Standard of Care
Predetermined standard of care drug and dosing

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Eisai Inc., National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of high frequency oscillations	The effect of perampanel on peritumoral hyperexcitability will be measured using intraoperative electrocorticography (ECoG) at the time of initial glioma resection to analyze high frequency oscillations (80-500 Hz). The rate of high frequency oscillations over 10 minutes of recording in the tumor margins will be compared between participants receiving perampanel versus standard of care treatment.	Peri-operative
Secondary	Seizure-free rates	The clinical effect of perampanel maintenance therapy on seizure control will be measured by seizure-free rates between the time of initial glioma resection and radiographic tumor progression (up to a maximum of 12 months), and compared to seizure-free rates in participants receiving standard of care treatment.	Up to 12 months